Polynucleotides encoding IL-31 monoclonal antibodies

• US 9,156,909 B2
• Filed: 09/19/2013
• Issued: 10/13/2015
• Est. Priority Date: 05/06/2005
• Status: Active Grant

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: Siadak, Anthony W., Bilsborough, Janine, Rene, Shirley
• Primary Examiner(s): MERTZ, PREMA MARIA
• Application Number:
  US14/031,963
• Publication Number:
  US 20140080181A1
• Time in Patent Office: 754 Days
• Field of Search: 435/69.6, 435/325, 435/252.3, 536/23.53
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 17/14 for baldness or alopecia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/244 Interleukins [IL]
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.

Claims

1. An isolated polynucleotide encoding a monoclonal antibody or antigen-binding fragment thereof that specifically binds to a polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:

2, wherein the monoclonal antibody or antigen-binding fragment thereof binds to the same epitope as the antibody produced by the hybridoma having ATCC Patent Deposit Designation PTA-6815 for binding to the polypeptide.

2. The polynucleotide of claim 1, wherein the monoclonal antibody is the antibody produced by the hybridoma having ATCC Patent Deposit Designation PTA-6815.

3. The polynucleotide of claim 2, wherein the monoclonal antibody is humanized.

4. The polynucleotide of claim 3, wherein the humanized monoclonal antibody comprises a human immunoglobulin constant region.

5. The polynucleotide of claim 3, wherein the isotype of the humanized monoclonal antibody is IgG.

6. The polynucleotide of claim 1, wherein the antigen-binding fragment is a Fab, Fab′

, F(ab′

)₂, or single chain Fv.

7. An isolated vector comprising the polynucleotide of claim 1.

8. An isolated host cell comprising the vector of claim 7.

9. A method of producing a monoclonal antibody or antigen-binding fragment thereof that specifically binds to a polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:

2 comprising;

a) culturing the host cell of claim 8 under conditions wherein the monoclonal antibody or antigen-binding fragment is expressed; and

b) recovering the monoclonal antibody or antigen-binding fragment.